HomeInsightsPE

Alembic Pharmaceuticals Ltd PE Ratio

Alembic Pharmaceuticals Ltd PE Ratio

stocks purchased

₹ 0.5 Cr

Volume Transacted

(Dec 11, 2024)

stocks purchased

4.5 K

Stocks Traded

(Dec 11, 2024)

Last Updated on: Dec 11, 2024

Image

Alembic Pharmaceuticals Ltd

NSE: APLLTD

PE

34.1

Last updated on: Dec 11, 2024

Key Highlights

  • The P/E Ratio of Alembic Pharmaceuticals Ltd is 34.1 as of 11 Dec 12:56 PM .
  • The P/E Ratio of Alembic Pharmaceuticals Ltd changed from 17.1 on March 2019 to 31.4 on March 2024 . This represents a CAGR of 10.66% over 6 years.
  • The Latest Trading Price of Alembic Pharmaceuticals Ltd is ₹ 1088 as of 11 Dec 12:50 .
  • The PE Ratio of Pharmaceuticals Industry has changed from 28.2 to 27.1 in 5 years. This represents a CAGR of -0.79%.
  • The PE Ratio of Automobile industry is 20.3. The PE Ratio of Finance industry is 17.8. The PE Ratio of IT - Software industry is 30.5. The PE Ratio of Pharmaceuticals industry is 40.0. The PE Ratio of Retail industry is 157.6. The PE Ratio of Textiles industry is 37.6 in 2024.

Historical P/E Ratio of Alembic Pharmaceuticals Ltd

No data available

Company Fundamentals for Alembic Pharmaceuticals Ltd

No data available

Image

Alembic Pharmaceuticals Ltd

NSE: APLLTD

Share Price

₹ 1088.95

-14.80 (-1.34%)

stock direction

Last updated on: Dec 11, 2024

Market Price of Alembic Pharmaceuticals Ltd

1M

1Y

3Y

5Y

Monitoring Alembic Pharmaceuticals Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
10 Dec 20241103.75
09 Dec 20241103.2
06 Dec 20241084.25
05 Dec 20241087
04 Dec 20241094.9
03 Dec 20241100.4
02 Dec 20241102.4
29 Nov 20241089.2
28 Nov 20241081.45
27 Nov 20241088.45

SWOT Analysis Of Alembic Pharmaceuticals Ltd

Strength

1

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Alembic Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

Asset Value vs Market Value of Alembic Pharmaceuticals Ltd

Market Value

0

Asset Value

0

* All values are in Rupees

Competitive Comparison of P/E Ratio

Company NamePEMarket Cap (INR Cr.)
Alembic Pharmaceuticals Ltd3421,695
Sun Pharmaceuticals Industries Ltd384,34,148
Divis Laboratories Ltd851,57,464
Cipla Ltd251,17,560
Torrent Pharmaceuticals Ltd651,13,318
Mankind Pharma Ltd501,06,927

Key Valuation Metric of Alembic Pharmaceuticals Ltd

No data available

No data available

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Historical Market Cap of Alembic Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Revenue of Alembic Pharmaceuticals Ltd

No data available

* All values are in crore

Historical EBITDA of Alembic Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Net Profit of Alembic Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Dividend Payout of Alembic Pharmaceuticals Ltd

No data available

* All values are in %

About Alembic Pharmaceuticals Ltd

  • Alembic Pharmaceuticals manufactures and markets generic pharmaceutical products all over the world.
  • The company's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. The company is one of the leaders in branded generics in India. Alembic Pharmaceuticals Ltd was incorporated on June 16, 2010 as a wholly owned subsidiary of Alembic Ltd. The company is engaged in pharmaceuticals business.
  • As per the scheme of arrangement, the 'Pharmaceutical Undertaking' of the Alembic Ltd was demerged and transferred to the company with effect from appointed date, April 1, 2010. In April 15, 2011, the company ceased to be a subsidiary of Alembic Ltd consequent to the allotment of 13,35,15,914 equity shares of Rs 2 each to the shareholders of Alembic Ltd as per the scheme of arrangement.

Alembic Pharmaceuticals Ltd News Hub

News

Alembic Pharma receives USFDA approval for Dabigatran Etexilate Capsules

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration...

Read more

2024-08-13 00:00:00

News

Alembic Pharma gets US FDA nod for anticoagulant Dabigatran

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD)...

Read more

2024-08-13 00:00:00

News

Alembic Pharmaceuticals Ltd leads losers in 'A' group

Steel Authority of India Ltd, IFCI Ltd, Coffee Day Enterprises Ltd and Orient Cement Ltd a...

Read more

2024-08-09 00:00:00

News

Alembic Pharma Q1 PAT rises 12% YoY to Rs 135 cr

Revenue from operations grew 5.09% year on year (YoY) to Rs 1,561.73 crore in the quarter ...

Read more

2024-08-08 00:00:00

Product Composition

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for PE of Alembic Pharmaceuticals Ltd

What is the current PE Ratio of Alembic Pharmaceuticals Ltd?

The Current PE Ratio of Alembic Pharmaceuticals Ltd is 34.07 as on 11 Dec 2024.

What is the average PE Ratio of the Pharmaceuticals industry?

The average industry PE Ratio of Pharmaceuticals is 40.0 as on 11 Dec 2024.

What was the PE Ratio of Alembic Pharmaceuticals Ltd last year?

The PE Ratio of Alembic Pharmaceuticals Ltd was 28.5 last year, now the PE ratio is 34.07, showing a year-on-year growth of 19.5%.

What does the PE Ratio of Alembic Pharmaceuticals Ltd indicate about its stock?

The PE Ratio of Alembic Pharmaceuticals Ltd is 34.07. This ratio indicates that investors are willing to pay 34.07 times the earnings per share for each share of Alembic Pharmaceuticals Ltd.

What is the PE Ratio Growth of Alembic Pharmaceuticals Ltd in comparison to its Earnings per Share (EPS) growth rate?

The PE Ratio of Alembic Pharmaceuticals Ltd grew by 19.5% whereas, the EPS ratio grew by 13.9.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Demat Account
Verify your phone
+91
*By signing up you agree to our terms & conditions